U.S. flag

An official website of the United States government

NM_002878.4(RAD51D):c.26G>C (p.Cys9Ser) AND Malignant tumor of breast

Germline classification:
Uncertain significance (1 submission)
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001357793.3

Allele description [Variation Report for NM_002878.4(RAD51D):c.26G>C (p.Cys9Ser)]

NM_002878.4(RAD51D):c.26G>C (p.Cys9Ser)

Genes:
RAD51D:RAD51 paralog D [Gene - OMIM - HGNC]
RAD51L3-RFFL:RAD51L3-RFFL readthrough [Gene]
Variant type:
single nucleotide variant
Cytogenetic location:
17q12
Genomic location:
Preferred name:
NM_002878.4(RAD51D):c.26G>C (p.Cys9Ser)
Other names:
p.C9S:TGC>TCC
HGVS:
  • NC_000017.11:g.35119588C>G
  • NG_031858.1:g.5282G>C
  • NG_054719.1:g.3010C>G
  • NM_001142571.2:c.26G>C
  • NM_002878.4:c.26G>CMANE SELECT
  • NM_133629.3:c.26G>C
  • NP_001136043.1:p.Cys9Ser
  • NP_002869.3:p.Cys9Ser
  • NP_002869.3:p.Cys9Ser
  • NP_598332.1:p.Cys9Ser
  • LRG_516t1:c.26G>C
  • LRG_516:g.5282G>C
  • LRG_516p1:p.Cys9Ser
  • NC_000017.10:g.33446607C>G
  • NM_001142571.1:c.26G>C
  • NM_002878.3:c.26G>C
  • NR_037711.2:n.171G>C
  • NR_037712.2:n.171G>C
  • p.C9S
Protein change:
C9S
Links:
dbSNP: rs140825795
NCBI 1000 Genomes Browser:
rs140825795
Molecular consequence:
  • NM_001142571.2:c.26G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_002878.4:c.26G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_133629.3:c.26G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NR_037711.2:n.171G>C - non-coding transcript variant - [Sequence Ontology: SO:0001619]
  • NR_037712.2:n.171G>C - non-coding transcript variant - [Sequence Ontology: SO:0001619]

Condition(s)

Name:
Malignant tumor of breast
Synonyms:
Malignant breast neoplasm; Cancer breast
Identifiers:
MONDO: MONDO:0007254; MedGen: C0006142

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001553375Department of Pathology and Laboratory Medicine, Sinai Health System - The Canadian Open Genetics Repository (COGR)

See additional submitters

no assertion criteria provided
Uncertain significanceunknownclinical testing

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedunknownyesnot providednot providednot providednot providednot providedclinical testing

Details of each submission

From Department of Pathology and Laboratory Medicine, Sinai Health System - The Canadian Open Genetics Repository (COGR), SCV001553375.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

The RAD51D p.Cys9Ser variant was identified in 9 of 12002 proband chromosomes (frequency: 0.0007) from Spanish, British and American individuals or families with BRCA1/2 negative breast/ovarian cancer or ovarian cancer and was identified in 3 of 7674 chromosomes from healthy individuals (Gutierrez-Enriquez 2013, Loveday 2011, Wickramanayake 2012, Song 2015). A case-control study of 3,429 patients with invasive ovarian cancer (unselected for family history) and 2,772 controls sequenced for RAD51B/C/D mutations found that RAD51C and RAD51D are moderate ovarian cancer susceptibility genes (Song 2015). The variant was identified in dbSNP (ID: rs140825795) “With Uncertain significance allele”, ClinVar (classified uncertain significance by GeneDx, Ambry Genetics, Invitae, Counsyl, Color Genomics Inc. and Quest Diagnostics Nichols Institute San Juan Capistrano), Clinvitae (3x), and was not identified in Cosmic or LOVD 3.0. The variant was also identified in control databases in 109 (1 homozygous) of 273460 chromosomes at a frequency of 0.0004 (Genome Aggregation Database Feb 27, 2017). It was observed in the following populations: African in 4 of 23938 chromosomes (freq: 0.0002), “Other” in 2 of 6436 chromosomes (freq: 0.0003), Latino in 13 (1 homozygous) of 34392 chromosomes (freq: 0.0004), European Non-Finnish in 88 of 124366 chromosomes (freq: 0.0007), European Finnish in 2 of 24602 chromosomes (freq: 0.00008); it was not observed in the Ashkenazi Jewish, East Asian, and South Asian populations. The p.Cys9Ser residue is conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1unknownyesnot providednot providednot providednot providednot providednot providednot provided

Last Updated: May 7, 2024